MedTrace Logo

Evaluation of Volatile Organic Compounds in Mepolizumab Therapy

NCT04924478 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-06-14

No results posted yet for this study

Summary

This study will recruit patients who are being prescribed Mepolizumab as part of their standard clinical care for the treatment of severe eosinophilic asthma. Over the course of their treatment, research data (questionnaires) and research samples (blood, breath and urine) will be collected in parallel to standard clinical measurements.

The data and samples will be investigated to help better understand how Mepolizumab works, why it doesn't work in certain patients and why it works very well in others. This will help prescribers better identify patients that will benefit from Mepolizumab.

Conditions

  • Asthma; Eosinophilic

Interventions

BIOLOGICAL

Mepolizumab

Patients will be receiving this treatment as part of their standard clinical care

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Adnan Azim, MBBS · University Hospital Southampton NHS Foundation Trust

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04924478 on ClinicalTrials.gov